Title : Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors.

Pub. Date : 2011 Mar 1

PMID : 20945321






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Although both are potent and specific BCR-ABL TKIs, dasatinib and nilotinib exhibit unique pharmacologic profiles and response patterns relative to different patient characteristics, such as disease stage and BCR-ABL mutation status. Dasatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens